CD79a

CD79a

a type I transmembrane protein present on B cells that mediates signal transduction; expressed in mature B-cell neoplasms.
References in periodicals archive ?
Immunophenotypically, neoplastic cells express CD20, CD79a, CD21 and CD35.
Those lymphoma cells expressed diffuse positive immunohistochemical stain for CD20, CD79a, CD5, and cyclin D1, but were negative for CD10, CD23, BCL6, and MUM1.
Atypical cells CD2, CD3, CD5, CD7, and TIA1 were found positive, CD20, CD79a, and CD117 were found negative, and MPO myeloid cells were positive.
The neoplastic lymphocytes in PCFCL express B-cell markers (CD19, CD20, CD22, CD79a, PAX5) and at least one follicle center marker, which is usually BCL6 or, less commonly, CD10 (Figure 2, D and E).
They express plasma cell markers (CD38, CD138), instead of pan B-cell markers (CD20, CD79a) of typical DLBCL.
Immunohistochemistry studies demonstrated B cells that were positive for CD79a and CD20 (figure 2, B).
Immunohistochemical analysis revealed that [beta]-cells expressed monotypic surface IgM, CD19, CD20, CD79a, CD10, and BCL6, with Ki-67 proliferative fraction >95%, which were diagnostic for BL.
Commonly expressed CD markers on T-lymphocytes include CD2, CD3, CD5, CD7 while CD19, CD20, CD22, CD79a are common markers expressed on B cell.
As listed in Table 2, the adherent cells from all of the five donors in the xeno-free medium had a similar expression profile of the following cell surface markers: positive expression of CD29, CD44, CD73, CD90, and CD166 and negative expression of CD14, CD34, CD45, CD79a, CD105, CD146, CD271, HLA-DR, SSEA-4, and Stro-1.
Immunophenotyping of bone marrow cells further supported the diagnosis of BCL, with the population testing positive for CD45, CD19, CD20, CD79a, and HLA-DR (Figures 2 and 3); however, terminal deoxynucleotidyl transferase expression in bone marrow cells was negative.